Literature DB >> 31919443

Grail of RAS cancer drugs within reach.

Cormac Sheridan1.   

Abstract

Entities:  

Year:  2020        PMID： 31919443     DOI： 10.1038/s41587-019-0382-x

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  8 in total

Review 1.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

2.  Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

Authors:  Özgün Babur; Alexander R Melrose; Jennifer M Cunliffe; John Klimek; Jiaqing Pang; Anna-Liisa I Sepp; Jevgenia Zilberman-Rudenko; Samuel Tassi Yunga; Tony Zheng; Iván Parra-Izquierdo; Jessica Minnier; Owen J T McCarty; Emek Demir; Ashok P Reddy; Phillip A Wilmarth; Larry L David; Joseph E Aslan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

3.  Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.

Authors:  E Giovannetti; C R Jimenez; T Y S Le Large; M F Bijlsma; B El Hassouni; G Mantini; T Lagerweij; A A Henneman; N Funel; B Kok; T V Pham; R de Haas; L Morelli; J C Knol; S R Piersma; G Kazemier; H W M van Laarhoven
Journal:  J Exp Clin Cancer Res       Date:  2021-03-09

Review 4.  Precision drugging of the MAPK pathway in head and neck cancer.

Authors:  Hoi-Lam Ngan; Chun-Ho Law; Yannie Chung Yan Choi; Jenny Yu-Sum Chan; Vivian Wai Yan Lui
Journal:  NPJ Genom Med       Date:  2022-03-16       Impact factor: 6.083

Review 5.  Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets.

Authors:  Alexandros Karagiannakos; Maria Adamaki; Antonis Tsintarakis; Borek Vojtesek; Robin Fåhraeus; Vassilis Zoumpourlis; Konstantinos Karakostis
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

6.  Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer.

Authors:  Hiroyuki Sayama; Diana Marcantonio; Takeyuki Nagashima; Masashi Shimazaki; Tsuyoshi Minematsu; Joshua F Apgar; John M Burke; Lucia Wille; Yasuhisa Nagasaka; Daniel C Kirouac
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-06-26

7.  SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.

Authors:  Carmine Fedele; Shuai Li; Kai Wen Teng; Connor J R Foster; David Peng; Hao Ran; Paolo Mita; Mitchell J Geer; Takamitsu Hattori; Akiko Koide; Yubao Wang; Kwan Ho Tang; Joshua Leinwand; Wei Wang; Brian Diskin; Jiehui Deng; Ting Chen; Igor Dolgalev; Ugur Ozerdem; George Miller; Shohei Koide; Kwok-Kin Wong; Benjamin G Neel
Journal:  J Exp Med       Date:  2021-01-04       Impact factor: 14.307

Review 8.  Mechanism of activation and the rewired network: New drug design concepts.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Chung-Jung Tsai; Bengi Ruken Yavuz; Nurcan Tuncbag; Hyunbum Jang
Journal:  Med Res Rev       Date:  2021-10-25       Impact factor: 12.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.